Toward Greater Diversity in Psychedelic Science.
Psychiatric services (Washington, D.C.) – February 05, 2026
Source: PubMed
Summary
A critical racial-ethnic disparity significantly limits the potential of psychedelic-assisted therapy. Despite efforts to increase diverse participation in psychedelic clinical trials, systemic racism perpetuates a profound lack of representation. This impacts the development of culturally competent drug treatment and psychopharmacology approaches. Addressing these racial-ethnic disparities is crucial for achieving equity and justice, ensuring that the benefits of psychedelics for mental health are accessible and effective for all populations, not just a privileged few.
Abstract
Racial-ethnic diversity is lacking in psychedelic science. Efforts have been made to increase racial-ethnic representation among clinical trial participant populations, but much work remains. This column aims to describe this disparity, outline potential benefits of eliminating this disparity, and provide recommendations for achieving equity and justice within the research landscape of psychedelic treatments for mental disorders.